The Japanese company Eisai gained the sole license to market , promote and distribute it as Zebinix or Exalief in Europe .
In 2008 , Bial completed clinical evaluation of eslicarbazepine acetate , a drug for the adjunctive use in partial seizures in adults with epilepsy .
The Japanese company Eisai gained the sole license to market , promote and distribute Bial as Zebinix or Exalief in Europe .
In 2008 , Bial completed clinical evaluation of eslicarbazepine acetate , a drug for the adjunctive use in partial seizures in adults with epilepsy .